ohn Flannery, CEO of GE Healthcare, has worked for General Electric for 30 years, but moved into health care only two-and-a-half years ago. He has had significant success since then, turning a division that was large but stagnant into an $18 billion money-maker. He talked recently with STAT about building a biopark, why applying data analytics to production is like craft brewing, and how his business is expanding into the developing world. This interview has been edited and condensed.

You’ve said that about half your business involves selling equipment and services to the biological drug production industry. What does that entail?

Seven or eight of the top 10 drugs now are biologic drugs. We have a role in supporting all of those drugs. We work closely with the drug companies and pharma companies as they’re researching and developing these drugs. The production process is really an integral part of the final approval of the drug itself, so we stay with these companies for years after these drugs come to market. It’s a good growth business for us.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.